Patients and Medical
Improving Pain Management and Mental Health in the Hemophilia Community: Let's Take Action
At the second Hemophilia Changemakers Event of this year, in partnership with Sanofi, advocates for people living with bleeding disorders...
Patients and Medical
Achieve global scale for your digital health solutions
In today's rapidly evolving healthcare landscape, pharmaceutical companies are increasingly recognizing the transformative potential of...
Latest
-
Patients and MedicalThe landscape of hemophilia care has undergone a remarkable transformation in recent decades, marked by momentous advancements in treatment, shifting societal attitudes, and an expanding scope of advocacy efforts.
-
Access and Evidence
How pharma is unleashing the benefits of real-world evidence along the value chain
Real-world evidence (RWE) is providing a fast track to approval and reimbursement. -
Multichannel
Using data to upgrade patient journeys
Collecting and analyzing patient data can improve all aspects of a patient’s health journey. Data privacy must never be compromised in the process. -
Patients and Medical
The complexities of designing a digital business model for seamless CGT commercialization
In navigating the era of cell and gene therapy, pharmaceutical firms must strategically engage stakeholders digitally while preserving space for personalized patient care amidst the digital landscape. -
Commercial
Global versus local: Mind the content gap
In the race to provide timely, tailored content for HCPs, pharma is rethinking its approach to how global and local content functions interact
Most Popular
Maria Aguirre G..., (Oct 24, 2023)
AI is transforming Medical Affairs by analyzing data and generating insights. We gathered experts to discuss its applications in the field.
Maria Aguirre G..., (Oct 25, 2023)
Advocates at the Hemophilia Changemakers Event emphasize holistic well-being for individuals with bleeding disorders, calling for improved pain management and mental health support
Maria Aguirre G..., (Oct 27, 2023)
Pharmaceutical companies should have a market launch strategy at least two years before data from a registrational clinical trial is available.
Opinion
Jill Donahue, (Mar 16, 2023)
For Zena Sfeir, Aitia VP Marketing, a strong sense of purpose is key to making an impact and improving lives
Jill Donahue, (Sep 5, 2022)
For Ana Paula Carvalho, President of Western Europe Cluster, Pfizer, her purpose began amidst overcoming challenges.
Commercial
-
Medical affairs: judicious analysis essential amid large datasets
With the increased use of healthcare technologies, leading to record volumes of data, pharma need to be strategic in extracting insights to drive their marketing strategy. -
Global versus local: Mind the content gap
In the race to provide timely, tailored content for HCPs, pharma is rethinking its approach to how global and local content functions interact -
The partnership powering omnichannel
Mastering omnichannel requires a close working relationship between marcomms and IT -
Centralize data and insights to avoid decision-making delays
To help boost patient-centricity, centralization of internal and external data allows for faster insight generation among pharmaceutical company teams. -
The Engagement Use Cases for AI
A wide array of AI tools are here now or coming that will help pharma sharpen its engagement approach across medical affairs and commercial.
Access and Evidence
-
How pharma is unleashing the benefits of real-world evidence along the value chain
Real-world evidence (RWE) is providing a fast track to approval and reimbursement. -
Tackle social determinants of health via data and community engagement
Social determinants of health can blur the safety and efficacy profiles of therapies, making it critical for the pharmaceutical industry to find ways to ease healthcare barriers. -
Transform patient-driven healthcare: Synthesize RWE and AI
The future of healthcare is here, and it's powered by real-world evidence (RWE) and artificial intelligence (AI), transforming patient care and clinical decision-making. -
How to develop out-of-the-box evidence collection strategies to boost approval rates
Enhanced evidence collection methodologies can improve approval rates and ensure reimbursement. Pharma companies should build an internal, cross-functional evidence team responsible for investigating new ways to collect and report clinical trial data -
RWE’s new dataset: Social media
Pharma is waking up to the potential of social media to enhance existing RWD sources and to offer altogether new insights in rare disease and beyond
Patients and Medical
-
Revolutionizing Hemophilia Advocacy: Unifying Voices for a Brighter Future
The landscape of hemophilia care has undergone a remarkable transformation in recent decades, marked by momentous advancements in treatment, shifting societal attitudes, and an expanding scope of advocacy efforts. -
The complexities of designing a digital business model for seamless CGT commercialization
In navigating the era of cell and gene therapy, pharmaceutical firms must strategically engage stakeholders digitally while preserving space for personalized patient care amidst the digital landscape. -
AI: The Key to Revolutionizing Medical Affairs?
The integration of AI in medical affairs signifies a transformative shift, enhancing efficiency in workflows, fostering personalized patient care, and necessitating a delicate balance between innovation and regulation -
Achieve global scale for your digital health solutions
Pharma companies are increasingly recognizing the potential of digital health solutions to transform the healthcare landscape, and many are looking to scale their digital initiatives globally. -
Improving Pain Management and Mental Health in the Hemophilia Community: Let's Take Action
Advocates at the Hemophilia Changemakers Event emphasize holistic well-being for individuals with bleeding disorders, calling for improved pain management and mental health support